Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b study of out-of-specification axicabtagene ciloleucel in indicated lymphoma patients
jRCT2013210008Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- May 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma, transformed (t-FL) and 1 more, sponsored by Gilead Sciences. Primary endpoint: Safety of non-standard commercial axicabtagene ciloleucel. Started May 2023; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma, transformed (t-FL)large-cell lymphoma
Beyond the preview
Go deeper on jRCT2013210008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013210008.